Illumina has delivered a sharp move over the past few years, and the big question now is whether the current US$214.91 share price is fully supported by the cash it can generate in the future. With fresh contract wins in precision medicine and new sequencing offerings in the pipeline, the stock now invites a closer look at how those developments might translate into long term cash flows.
- Illumina has returned 120.8% over the past 3 years, which puts real weight on whether the underlying cash flows can match the expectations now embedded in the share price.
- Recent wins such as Singapore's National Precision Medicine programme and new duplex sequencing technology for molecular residual disease research can influence future cash generation by shaping volumes, pricing power and investment needs across Illumina's sequencing platforms.
- Prefer to judge Illumina on earnings? See why Illumina's 36.3x P/E tells a different valuation story.
For investors, the debate is whether Illumina's current valuation is justified by the cash flows implied in its Discounted Cash Flow (DCF) intrinsic value estimate or if the market price is asking too much of the business.
If you are weighing Illumina against other ways to play genomics and related themes, it can help to compare it with 36 healthcare AI stocks.
Does Illumina Look Fairly Valued on Cash Flow?
The Discounted Cash Flow (DCF) approach here takes Illumina's projected future cash generation and brings it back to today's dollars. Latest twelve month free cash flow sits at about $1.08b, which gives the model a solid current base rather than relying solely on distant forecasts.
Analyst inputs and extrapolated estimates point to free cash flow that is growing rather than shrinking by 2030, with projected figures rising above $1.6b in that year. On those assumptions, the DCF outcome implies an intrinsic worth broadly in line with the current US$214.91 share price, so the market is already baking in a meaningful recovery story for Illumina's cash generation. Illumina raising its 2026 earnings guidance despite China related headwinds helps explain why the valuation now tracks the cash flow model more closely. Find out what Illumina could be worth using our Discounted Cash Flow (DCF) estimate.
The Illumina Narrative: What Would Justify Today's Price?
Narratives pick up where Illumina's DCF puzzle leaves off by explaining which paths for revenue growth, margins and earnings would need to occur for the stock to be worth materially more or materially less than today. They are available on Simply Wall St's Community page. Each narrative is framed as a clear, testable view of Illumina's fair value so you can track how that thesis holds up as the business evolves.
Bulls see Illumina as a clinical and data compounding story, while bears focus on legal, cost and competitive pressures tightening the screws.
Bull case: 40% undervalued
The bullish analyst Narrative on Simply Wall St frames Illumina as a clinical sequencing and multiomics engine with more earnings power to come.
"Illumina’s push to move clinical sequencing toward standard use in oncology, rare disease and reproductive health, with clinical consumables already about 65% of sequencing consumables and growing 15 to 20% ex China in early 2026, gives room for a larger installed base of high frequency users that could deepen recurring consumables demand…"
Discover why this Narrative puts Illumina at 40% undervalued.
Bear case: 30% overvalued
The bearish analyst Narrative on Simply Wall St argues that legal disputes, higher costs and new rivals leave Illumina with little slack in expectations.
"Despite NovaSeq X placements running ahead of plan and a high share of high throughput volume already transitioned, the launch of Roche’s Axelios 1 system at a US$750,000 price point introduces a direct high throughput competitor that could trigger pricing pressure and slower than expected consumables pull through…"
Explore why this Narrative puts Illumina at 30% overvalued.
One more Illumina factor to check before you act
Shares can look logically priced on cash flows while still depending heavily on who is in charge, how they think, and the way their incentives are wired. See who runs Illumina and how they are paid.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com